GlassScriptPhysician profile
Ateka Zaki
NPI 1053321042
$15,329.05
in general payments reported to CMS, 2019-2025
33 companies · $3,059 in 2025
The $3,059 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,588 · 2020: $1,674 · 2021: $1,947 · 2022: $2,133 · 2023: $2,904 · 2024: $2,025 · 2025: $3,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,705 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,705.01 |
| Education | $282.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,887.75 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $1,329.90 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,283.51 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,236.25 | 2021-2025 | Vraylar |
| Alkermes, INC. | $1,131.22 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Bausch Health US, LLC | $940.32 | 2019-2025 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $780.75 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Corium, LLC | $747.12 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $695.68 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $645.46 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Axsome Therapeutics, INC. | $529.94 | 2022-2025 | Auvelity, Sunosi |
| Neos Therapeutics, LP | $490.40 | 2019-2024 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $485.65 | 2019-2022 | |
| Lundbeck LLC | $446.65 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $358.87 | 2021-2025 | Qelbree, Qelbree |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $335.69 | 2019-2024 | Sublocade, Perseris |
| Ironshore Pharmaceuticals INC. | $327.10 | 2019-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $296.80 | 2020-2025 | Xelstrym, Secuado |
| Tris Pharma INC | $251.28 | 2019-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $218.49 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $177.52 | 2022-2025 | Ingrezza |
| Eisai INC. | $166.64 | 2020-2022 | |
| Adlon Therapeutics L.P. | $109.25 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $96.16 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $93.03 | 2023-2025 | Quviviq, Quviviq |
| Shire North American Group INC | $72.50 | 2019 | |
| Almatica Pharma LLC | $50.03 | 2024-2025 | Loreev Xr |
| Livanova USA, INC. | $39.88 | 2021 | |
| Bioxcel Therapeutics, INC. | $30.19 | 2024 | Igalmi |
| Vertical Pharmaceuticals, LLC | $23.69 | 2024 | Relexxii |
| Jazz Pharmaceuticals INC. | $20.41 | 2021 | |
| Allergan, INC. | $16.36 | 2020 | |
| Neuronetics, INC. | $14.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ateka Zaki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.